QureBio Ltd. Reveals Q-1802 Phase II Results at ASCO 2026 Conference

On January 28, 2026, QureBio Ltd., a notable player in the clinical-stage biotech sector, announced significant updates on its bispecific antibody Q-1802 at the ASCO 2026 conference. This event showcased important findings from their Phase Ib/II clinical trials targeting advanced gastric cancer (GC) and gastroesophageal junction cancer (GEJ).

About Q-1802 and its Clinical Trials

The report shared by QureBio details the experiences of 62 participants with CLDN18.2-positive, HER2-negative, histologically confirmed unresectable locally advanced or metastatic GC/GEJ, who had not yet received treatment. These patients were administered Q-1802 in conjunction with the standard XELOX regimen, at dosages of either 10 mg/kg or 20 mg/kg every two weeks.

Notably, the safety profile of Q-1802 remained favorable throughout the trial. No dose-limiting toxicities (DLTs) were detected, and the maximum tolerated dose (MTD) was not reached. The most frequently reported adverse events related to Q-1802 were grade 3 or higher thrombocytopenia (8.1%) and neutropenia (6.5%). Other effects included anemia and reductions in white blood cell counts, making the overall treatment tolerable with no attributed deaths.

Efficacy Outcomes

Among the 60 patients eligible for efficacy evaluation, Q-1802 yielded an objective response rate (ORR) of 70%, with disease control rate (DCR) at an impressive 98.3%, and a median progression-free survival (mPFS) of 11.3 months. Notably, those in the 10 mg/kg cohort with high expression of CLDN18.2 (≥40% tumor cells with 2+/3+ staining) achieved even better results, achieving an ORR of 73% and maintaining an mPFS of 11.3 months. Furthermore, patients where CLDN18.2 high expression was paired with a PD-L1 clinical positive score (CPS) of 5 or greater experienced enhanced outcomes with an ORR of 81.8% and mPFS of 12.2 months.

The conclusion drawn by the research team led by Dr. Gong was clear: Q-1802, when combined with XELOX, showcases both manageable safety and promising antitumor activity for first-line treatment in the targeted patient demographic. The data strongly supports the initiation of a phase III trial with Q-1802’s recommended dosage set at 10 mg/kg.

Future Perspectives and Developments

In an exciting turn for the company, Q-1802 has recently received approval from the Chinese Center for Drug Evaluation (CDE) to progress to phase III trials. This landmark approval signals a substantial step forward for QureBio in its mission to bring innovative cancer therapies to market.

About QureBio Ltd.

Founded in 2017, QureBio Ltd. is dedicated to developing biopharmaceuticals that address pressing clinical needs linked to oncological diseases, inflammation, and various serious disorders. By harnessing state-of-the-art technologies, including platforms for bispecific and tri-specific antibodies, the company continues to push the boundaries of biopharmaceutical innovations. Fueled by investments from several venture capital firms and collaborations with partners like Precision Scientific and Hengrui Pharmaceuticals, QureBio is setting the stage for groundbreaking advancements in treatment methodologies.

As QureBio prepares for expanded clinical trials, it embarks on a journey that not only aims to redefine cancer treatment but also holds the potential to deliver hope to countless patients facing severe health challenges.